2024 Beigeneius logo_v1.0

BeiGeneius Spotlight Series

Learn about the latest developments in lung cancer and hematologic malignancies

Spotlights

20240705_BeiMedPlus_BeiGeneius_shortvideos_Fallowfield 00:02:41

Difficult conversations in hematology: Discussing clinical trial enrolment with a patient

20240705_BeiMedPlus_BeiGeneius_shortvideos_Fallowfield 00:03:01

Difficult conversations in hematology: Presenting treatment options for indolent lymphomas

20240705_BeiMedPlus_BeiGeneius_shortvideos_Zinzani 00:02:22

A new era for BTK inhibitors in the management of B-cell lymphomas

20240705_BeiMedPlus_BeiGeneius_shortvideos_Eichhorst 00:04:11

An expert perspective on what developments to expect in CLL in 2024

20240705_BeiMedPlus_BeiGeneius_shortvideos_Eichhorst 00:04:42

ASH 2023 updates: RT1 study of tislelizumab plus zanubrutinib in Richter transformation

20240705_BeiMedPlus_BeiGeneius_shortvideosTam 00:02:51

ASH 2023 updates: ALPINE study of zanubrutinib vs. ibrutinib in R/R CLL

20240705_BeiMedPlus_BeiGeneius_shortvideosTam 00:03:05

ASH 2023 updates: Switching BTK inhibitor monotherapy

20240705_BeiMedPlus_BeiGeneius_shortvideosTam 00:04:25

ASH 2023 updates: Acquired mutations on BTK inhibitor-containing therapies

20240705_BeiMedPlus_BeiGeneius_shortvideosTam 00:05:18

ASH 2023 updates: Fixed-duration therapy for CLL with a BTK plus BCL2 inhibitor

20240705_BeiMedPlus_BeiGeneius_shortvideos_Patel 00:09:17

WCLC 2023 and ESMO 2023 highlights: Refractory SCLC

20240705_BeiMedPlus_BeiGeneius_shortvideos_Patel 00:05:00

WCLC 2023 highlights: RATIONALE-312

20240705_BeiMedPlus_BeiGeneius_shortvideos_Paz-Ares 00:05:55

ESMO 2023 highlights: RATIONALE-315

20240705_BeiMedPlus_BeiGeneius_shortvideos_Patil_Camidge 00:10:02

WCLC 2023 highlights: MARS 2 trial background

20240705_BeiMedPlus_BeiGeneius_shortvideos_Patil_Camidge 00:08:51

WCLC 2023 highlights: MARS 2 trial results and impact

20240705_BeiMedPlus_BeiGeneius_shortvideosSchenk 00:05:59

WCLC 2023 highlights: FLAURA2 trial

20240705_BeiMedPlus_BeiGeneius_shortvideosSchenk 00:06:48

ASCO 2023 highlights: KEYNOTE-671 and ADAURA trials

20240705_BeiMedPlus_BeiGeneius_shortvideos_Mok 00:06:11

ASCO 2023 highlights: LUNAR trial

20240705_BeiMedPlus_BeiGeneius_shortvideos_Mok 00:01:58

ASCO 2023 highlights: CHOICE-01 trial

20240705_BeiMedPlus_BeiGeneius_shortvideos_Mok 00:03:53

ASCO 2023 highlights: TROPION-Lung02 trial

20240705_BeiMedPlus_BeiGeneius_shortvideos_wendtner 00:06:11

The 2023 update to the Onkopedia CLL guidelines

20240705_BeiMedPlus_BeiGeneius_shortvideos_Buske.jpg 00:02:33

The role of BTK inhibitors and genetic testing in Waldenström’s macroglobulinemia

20240705_BeiMedPlus_BeiGeneius_shortvideos_Buske.jpg 00:03:18

Managing toxicity with BTK inhibitors in Waldenström’s macroglobulinemia

20240705_BeiMedPlus_BeiGeneius_shortvideos_Tedeschi 00:04:44

ASH 2023 updates: BTK inhibitor monotherapy for treatment-naive CLL